铁螯合剂去铁胺可降低骨髓瘤细胞的存活率。
The iron chelator deferoxamine decreases myeloma cell survival.
机构信息
Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
出版信息
J Int Med Res. 2021 Jan;49(1):300060520987396. doi: 10.1177/0300060520987396.
OBJECTIVE
This study evaluated serum ferritin (SF) levels and investigated their relationships with various clinical markers in patients with multiple myeloma (MM). Furthermore, the effects and molecular mechanism of deferoxamine (DFO) in myeloma cells were studied.
METHODS
Clinical data from 84 patients with MM were collected to evaluate SF content and its relationship with several important clinical parameters. MM1S and MM1R myeloma cells were chosen to investigate the effects of iron and DFO on cell survival and apoptosis.
RESULTS
Increased SF levels were detected in newly diagnosed patients, especially those with stage III disease or the κ isotype. SF content was positively correlated with β2-microglobulin, interleukin-6, and lactate dehydrogenase expression. Furthermore, patients with progressive or relapsed disease had higher SF levels. Importantly, iron chelation with DFO efficiently inhibited myeloma cell survival and accelerated apoptosis by regulating apoptosis-related genes.
CONCLUSIONS
The importance of SF for MM was highlighted. Additionally, it is suggested that DFO may be a good therapeutic option for MM.
目的
本研究评估了多发性骨髓瘤（MM）患者的血清铁蛋白（SF）水平，并探讨了其与各种临床标志物的关系。此外，还研究了去铁胺（DFO）在骨髓瘤细胞中的作用及其分子机制。
方法
收集 84 例 MM 患者的临床资料，评估 SF 含量及其与几个重要临床参数的关系。选择 MM1S 和 MM1R 骨髓瘤细胞，研究铁和 DFO 对细胞存活和凋亡的影响。
结果
新诊断患者的 SF 水平升高，尤其是 III 期疾病或κ 型患者。SF 含量与β2-微球蛋白、白细胞介素-6 和乳酸脱氢酶的表达呈正相关。此外，进展或复发疾病患者的 SF 水平更高。重要的是，铁螯合剂 DFO 通过调节凋亡相关基因，有效地抑制骨髓瘤细胞的存活并加速其凋亡。
结论
SF 对 MM 具有重要意义。此外，DFO 可能是 MM 的一种较好的治疗选择。
Zotero 插件